SOD1 and amyotrophic lateral sclerosis: In the aforementioned placebo-controlled VALOR trial investigating the use of the intrathecally administered ASO (tofersen) in SOD1-caused ALS, there was a significant reduction in CSF NfL levels in the treatment arm compared to the placebo arm.